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The purpose of this study was to use serial imaging to gain insight into the sequence of pathologic events in Alzheimer’s
disease, and the clinical features associated with this sequence. We measured change in amyloid deposition over time using
serial
11C Pittsburgh compound B (PIB) positron emission tomography and progression of neurodegeneration using serial
structural magnetic resonance imaging. We studied 21 healthy cognitively normal subjects, 32 with amnestic mild cognitive
impairment and 8 with Alzheimer’s disease. Subjects were drawn from two sources—ongoing longitudinal registries at Mayo
Clinic, and the Alzheimer’s disease Neuroimaging Initiative (ADNI). All subjects underwent clinical assessments, MRI and PIB
studies at two time points, approximately one year apart. PIB retention was quantiﬁed in global cortical to cerebellar ratio units
and brain atrophy in units of cm
3 by measuring ventricular expansion. The annual change in global PIB retention did not differ
by clinical group (P=0.90), and although small (median 0.042 ratio units/year overall) was greater than zero among all subjects
(P50.001). Ventricular expansion rates differed by clinical group (P50.001) and increased in the following order: cognitively
normal (1.3cm
3/year) 5amnestic mild cognitive impairment (2.5 cm
3/year) 5Alzheimer’s disease (7.7 cm
3/year). Among all
subjects there was no correlation between PIB change and concurrent change on CDR-SB (r=0.01, P=0.97) but some evidence
of a weak correlation with MMSE (r=0.22, P=0.09). In contrast, greater rates of ventricular expansion were clearly correlated
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model of typical late onset Alzheimer’s disease that has two main features: (i) dissociation between the rate of amyloid
deposition and the rate of neurodegeneration late in life, with amyloid deposition proceeding at a constant slow rate while
neurodegeneration accelerates and (ii) clinical symptoms are coupled to neurodegeneration not amyloid deposition. Signiﬁcant
plaque deposition occurs prior to clinical decline. The presence of brain amyloidosis alone is not sufﬁcient to produce cognitive
decline, rather, the neurodegenerative component of Alzheimer’s disease pathology is the direct substrate of cognitive impair-
ment and the rate of cognitive decline is driven by the rate of neurodegeneration. Neurodegeneration (atrophy on MRI) both
precedes and parallels cognitive decline. This model implies a complimentary role for MRI and PIB imaging in Alzheimer’s
disease, with each reﬂecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration.
Keywords: Alzheimer’s disease; amyloid imaging; magnetic resonance imaging, longitudinal imaging; mild cognitive impairment;
Pittsburgh compound B
Abbreviations: AD=Alzheimer’s disease; MCI=mild cognitive impairment; CN=cognitively normal; MRI=magnetic resonance
imaging; PIB=
11C Pittsburgh compound B
Introduction
Alzheimer’s disease pathology can be broadly thought of in three
classes: (i) amyloid dysmetabolism, characterized pathologically by
amyloid plaque formation (ii) neuroﬁbrillary tangle formation, and
(iii) neurodegeneration, characterized pathologically by neuroﬁbril-
lary tangle formation, and ultrastructurally by loss of neurons,
synapses and dendritic arborization (Braak and Braak, 1991;
Terry et al., 1991). Given that these qualitatively different pathol-
ogies characterize Alzheimer’s disease, it is reasonable to ask if
they arise simultaneously and progress in lockstep, or if they
have different time courses.
Imaging modalities can be thought of as in vivo indicators of
speciﬁc pathologies. Amyloid labelling PET ligands, such as
11C Pittsburgh compound B (PIB) primarily measure brain amyloid
plaque load (Klunk et al., 2004; Rowe et al., 2007; Drzezga
et al., 2008; Ikonomovic et al., 2008; Leinonen et al., 2008) but
also localize in cerebral vascular amyloid (Bacskai et al., 2007;
Johnson et al., 2007; Lockhart et al., 2007). Structural MRI, on
the other hand, is an in vivo indicator of neurodegeneration
(Bobinski et al., 2000; Gosche et al., 2002; Jack et al., 2002;
Silbert et al., 2003;Csernansky et al., 2004; Zarow et al., 2005;
Jagust et al., 2008; Vemuri et al., 2008; Whitwell et al., 2008).
Serial multi-modality imaging studies which are sensitive to the
different aspects of Alzheimer’s disease pathology are an ideal
way to answer questions about the temporal sequencing of
different pathologic features of the disease.
In this study we measured change in amyloid deposition over time
using PIB PET and progression of neurodegeneration using structural
MRI, with time-locked serial imaging studies. We did this in subjects
who were located at three clinically deﬁnable points along the dis-
ease trajectory in Alzheimer’s disease: healthy cognitively normal
controls (CN), subjects with amnestic MCI (aMCI) and subjects
with Alzheimer’s disease. Subjects were drawn from two sources:
ongoing longitudinal registries at Mayo Clinic and the Alzheimer’s
disease Neuroimaging Initiative (ADNI). The purpose of this study
was to use serial PIB and magnetic resonance imaging to gain insight
into the sequence of pathologic events in Alzheimer’s disease, and
the clinical features associated with this sequence.
Methods
Sources of subjects and diagnostic
evaluation at Mayo
Twenty-three subjects were studied at Mayo; 10 cognitively normal,
nine amnestic mild cognitive impairment and four Alzheimer’s disease.
Of these, all 10 cognitively normal subjects and eight of the MCI
subjects were recruited from the Mayo Clinic Study of Aging
(MCSA), an epidemiologic study of normal ageing and MCI in indivi-
duals aged 70–90 years in Rochester, Olmsted County, Minnesota.
The remaining amnestic MCI subject and the four Alzheimer’s
disease subjects were drawn from the Mayo Alzheimer’s disease
research center (ADRC). ADRC recruitment is drawn from individ-
uals seeking medical care at the Mayo Clinic and, therefore, these
subjects were typical of those seen at a tertiary referral centre. Both
the MCSA and ADRC are longitudinal studies which include serial
clinical and cognitive assessments, MRI, with the recent addition
of PIB studies.
At baseline, all subjects met diagnostic criteria for cognitively
normal, amnestic MCI, or Alzheimer’s disease. Categorization into
diagnostic groups was made on a clinical basis at consensus confer-
ences including neurologists, neuropsychologists, a neuropsychiatrist
and study coordinators. Cognitively normal subjects were asymp-
tomatic cognitively normal volunteers. Criteria for the categorization
of cognitively normal were: (i) no active neurological or psychiatric
disorders; (ii) some subjects may have had ongoing medical problems,
yet the illnesses or their treatments did not interfere with cognitive
function; (iii) normal neurological exam and (iv) were independently
functioning community dwellers. Criteria for the diagnosis of amnestic
MCI were those of Petersen et al. (2001): (i) memory complaint docu-
mented by the patient and collateral source; (ii) relatively normal gen-
eral cognition; (iii) normal activities of daily living; (iv) not demented
(DSM-IV) and (v) memory impaired for age and education. In general,
the amnestic MCI determination is made when the memory measures
fall 1.0–1.5 SD below the means for age and education appropriate
individuals in our community; however, rigid cutoffs on psychometric
scores were not used to establish the diagnosis of amnestic MCI which
was made on clinical grounds. The diagnosis of dementia was made
using DSM-IV criteria (1994), and the diagnosis of Alzheimer’s disease
was made using established criteria (McKhann et al., 1984).
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evaluation in ADNI
Thirty-eight subjects were drawn from ADNI; 11 cognitively normal,
23 amnestic MCI and four Alzheimer’s disease. ADNI is a longitudinal
multisite observational study of elderly cognitively normal, amnestic
MCI and Alzheimer’s disease subjects. Subjects are recruited using a
variety of methods, including the local ADRC, memory clinics, news-
paper ads, radio and other public media campaigns. MRI and clinical/
psychometric assessments are performed annually in all subjects.
Additional information can be found at www.ADNI-info.org.
Subjects included in this study were enrolled at 11 sites that are
participating in a PIB substudy.
Clinical categorization criteria for ADNI subjects were largely the
same as described above for Mayo subjects. Criteria for cognitively
normal subjects were: Mini Mental State Exam (MMSE) scores
between 24 and 30, no memory complaints, objective memory
performance in the normal range, and a clinical dementia rating
(CDR) scale score of 0 (Folstein et al., 1975; Morris, 1993). ADNI
amnestic MCI subjects have MMSE scores in the 24–30 range, a
memory complaint veriﬁed by an informant, abnormal memory func-
tion and a CDR score of 0.5 with preservation of general cognition
and functional activities of daily living. Alzheimer’s disease patients
met published criteria for probable Alzheimer’s disease (McKhann
et al., 1984) with MMSE scores of 20–26 and CDR scores of 0.5–1.0.
Subject inclusion and continuous
measures of cognitive performance
With six exceptions, all cognitively normal, amnestic MCI and
Alzheimer’s disease subjects in whom serial MRI and PIB data were
available from Mayo and ADNI were included in this analysis. No other
criteria were used to select subjects for this study. We excluded one
ADNI cognitively normal subject with periventricular infarctions in
whom the serial ventricular measurements were unreliable. We
excluded ﬁve ADNI subjects in whom longitudinal PIB measurements
seemed unreliable. Published estimates indicate an expected test/retest
reliability of 7% for PIB imaging (Lopresti et al., 2005; Engler et al.,
2006). We operated from the premise that while increases in PIB
retention over time are plausible, large decreases are not. Therefore,
we excluded any case where the annual decline in PIB retention
exceeded 7% on the assumption that declines in PIB retention greater
than 7% exceeded currently accepted limits of reproducibility and
likely represented instances of unacceptable measurement error. The
ﬁve cases with declines greater than 7% that were excluded were
from two ADNI sites (three at one site and two at another).
For both Mayo and ADNI subjects, the Clinical Dementia Rating
scale—sum of boxes (CDR-SB) was used to assess functional perfor-
mance. For ADNI subjects, the MMSE was used to assess global
cognitive performance. For Mayo subjects, a 38-point test, the Short
Test of Mental Status (STMS) (Kokmen et al., 1991), was used to
assess global cognitive performance. In order to maintain consistency
with ADNI data, we converted Mayo STMS scores to MMSE scores
using an algorithm developed at our centre (Tang-Wai et al., 2003).
STMS values transformed to MMSE scores are reported simply as
MMSE throughout the manuscript.
PET acquisition
For both Mayo and ADNI subjects, production of PIB and radio label-
ling with
11C was performed as outlined by Mathis et al. (2003).
For Mayo subjects, at 25min post injection, a helical CT image was
obtained for attenuation correction. The PET acquisition consisted of
5min dynamic frames from 40 to 60min post injection. PET sinograms
were iteratively reconstructed into a 256mm FOV. The pixel size was
1.0mm and the slice thickness 3.3mm. Individual frames of the
PIB dynamic series were realigned if motion was detected and then
a mean image was created, referred to from here on as the late
uptake image.
ADNI PIB studies were performed at 11 different sites. The ADNI
PIB images undergo several quality control and standardization steps
which are described at www.ADNI-info.org. The ADNI late uptake PIB
images used in our study were the ‘maximally pre-processed ﬁles’
available for download. There was one signiﬁcant difference between
the Mayo and the ADNI PIB late uptake images; although both data
sets consisted of four 5min dynamic frames, ADNI PIB images were
acquired 50–70min post injection while the Mayo images were
acquired 40–60min post injection.
PIB image processing and atlas-based
brain parcellation for quantitative PIB
region of interest analysis
All PIB quantitative image analyses was performed at Mayo, using the
same fully automated image processing pipeline which is described in
detail (Jack et al., 2008b; Senjem et al., 2008). The method includes
region of interest sharpening of PIB images using each subject’s MRI.
The automated anatomic labelling (AAL) atlas (Tzourio-Mazoyer et al.,
2002) was modiﬁed in-house to contain the following labelled regions
of interest: right and left parietal, temporal, prefrontal, primary sensory
-motor, orbito frontal, anterior cingulate, posterior cingulate/
precuneus and occipital. Statistics on image voxel values were
extracted from each automatically labelled cortical region of interest
in the atlas. Right- and left-sided homologous PIB regions of interest
demonstrate high within subject intra-class correlation; therefore, the
right and left sides were combined for quantitative analyses (Jack
et al., 2008b; Raji et al., 2008). A global cortical PIB retention sum-
mary was formed by combining the prefrontal, orbito-frontal, parietal,
temporal, anterior cingulate and posterior cingulate/precuneus ratio
values for each subject, using a weighted average of these regions
of interest values where larger regions of interest were given greater
weight. PIB ratio images were calculated by dividing the median value
in each target cortical region of interest by the median value in the
cerebellar grey matter region of interest of the atlas. PIB data in the
manuscript are reported in cortical to cerebellar retention ratio units.
Measurement of PIB retention was performed independently on the
baseline and follow-up image volumes for each subject.
Throughout the results section, subjects are classiﬁed as either PIB
positive or PIB negative, using a global cortical to cerebellar ratio cut
point of 1.5 to separate the two groups (Jack et al., 2008b). While
inspection of the results will reveal that the PIB retention distribution is
continuous, many leading research groups have also described their
results dichotomously (positive versus negative) in order to map
continuous measures of PIB retention onto typically used clinical
notions of a normal versus abnormal test result (Pike et al., 2007;
Rabinovici et al., 2007; Aizenstein et al., 2008; Gomperts et al.,
2008; Mormino et al., 2008).
MRI acquisition
MRI acquisition protocols were very similar for Mayo and ADNI sub-
jects. There was one notable difference; although all subjects were
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were scanned at 3T while ADNI subjects were scanned at 1.5T. Mayo
subjects were imaged with a 3D magnetization prepared rapid acqui-
sition gradient echo (MPRAGE) imaging sequence developed at Mayo
for the Alzheimer’s Disease Neuroimaging Initiative study (Jack et al.,
2008a). Parameters were: sagittal plane, TR/TE/T1, 2300/3/900ms;
ﬂip angle 8, 26cm ﬁeld of view (FOV); 256256 in-plane matrix
with a phase FOV of 0.94 and slice thickness of 1.2mm.
ADNI collects 1.5T MRI scans in all subjects and 3T scans in only
25% of the sample; therefore ADNI 1.5T MRI scans were used for this
study. ADNI is a multi-site study and there are minor variations in the
MRI protocol based on the speciﬁc hardware/software conﬁguration
on each scanner. The nominal parameters of the ADNI MPRAGE were:
sagittal plane, TR/TE/T1, 2400/3/1000ms, ﬂip angle 8, 24cm FOV,
192192 in-plane matrix, 1.2mm slice thickness (Jack et al., 2008a).
All images were corrected for image distortion due to gradient
non-linearity using ‘GradWarp’ (Jovicich et al., 2006) and for intensity
inhomogeneity using ‘N3’ (Sled et al., 1998) using a software pipeline
running at Mayo. Post processing image corrections for Mayo and
ADNI scans were identical since the ADNI MRI core is centred at
Mayo.
MRI analysis
MRI-processing steps were performed by a research technician (MMS)
who was blinded to all clinical information. Brain atrophy was assessed
by measuring ventricular expansion rates using the boundary shift
integral (BSI) technique (Freeborough and Fox, 1997; Gunter et al.,
2003). Differences were calculated in pair-wise fashion between the
baseline scan and the follow up scan. Following spatial registration of
the follow up scan to the baseline scan, intensity differences between
the two scans at the brain-CSF boundary were used to compute
change in volume. The ventricular atrophy rate was derived by creat-
ing a binary ventricular mask for each subject that selectively extracted
ventricular change from the boundary shift integral. Quality control
testing in our laboratory shows that the intra-class correlation coefﬁ-
cient for test–retest reproducibility of ventricle rate measurements
from short interval serial MRI scans with this method is 0.91 which
is better than whole brain boundary shift integral (Jack et al., 2004). In
the context of this analysis, an additional advantage of casting atrophy
as ventricular expansion rather than brain shrinkage is that biological
worsening for both MRI and PIB go in the same direction (i.e. increas-
ing values mean worse pathology). Baseline ventricular volume was
measured from the ventricular mask, and was normalized for inter-
subject variation in head size by dividing ventricular volume by that
subject’s total intra-cranial volume (TIV) as described in Jack et al.
(1989).
Statistical methods
We used non-parametric methods to analyse numeric distributions in
order to have a consistent approach to analysing these data which
included skewed distributions. When comparing three groups simulta-
neously on numeric variables, we used the Kruskal–Wallis test. When
comparing two groups, we used the Wilcoxon rank-sum test. We used
Spearman rank-order correlations, which we denote simply by r,t o
evaluate associations between paired numeric measures. We analysed
categorical variables using chi-squared tests with continuity correction
unless one or more expected cell counts was less than one, in which
case Fisher’s exact test was used. We summarized numeric distribu-
tions graphically by showing individual values superimposed over
a box indicating the sample median and quartiles (i.e. the 25th,
50th and 75th percentiles). All P-values are two-sided. We did
not adjust our P-values for multiple comparisons (O’Brien, 1983;
Perneger, 1998). A complete discussion of our rationale can be
found in Perneger (1998).
Results
Demographic features by clinical
group and source
When reporting results we will refer to clinical diagnostic category
(cognitively normal versus amnestic MCI versus Alzheimer’s dis-
ease) as clinical ‘group’ and will denote subjects from Mayo and
ADNI as coming from different ‘sources’. Clinical and demographic
data are reported in Table 1, with accompanying P values for
group and source differences in Supplementary Table E1. Age,
Table 1 Subject demographics
Characteristics Cognitively normal Amnestic mild cognitive impairment Alzheimer’s disease
ADNI Mayo ADNI Mayo ADNI Mayo
Number of subjects 11 10 23 9 4 4
Age at ﬁrst PIB exam, median (range), years 72 (63–87) 75 (72–90) 75 (61–88) 79 (72–87) 70 (68–77) 66 (54–80)
Gender, no. (%) male 8 (73) 7 (70) 14 (61) 5 (56) 3 (75) 1 (25)
Education, median (range), years 14 (12–20) 16 (12–20) 16 (12–20) 12 (12–19) 16 (12–20) 16 (13–20)
APOE, no. (%) e4 carrier
a 2 (18) 3 (30) 14 (61) 2 (33) 1 (25) 1 (100)
MMSE, median (range) 29 (24–30) 28 (25–30) 27 (24–30) 27 (24–28) 24 (20–24) 22 (17–26)
CDR–SB, median (range)
a 0 (0–1) 0 (0–0.5) 1.5 (0.5–4) 1.5 (0–3) 5 (4–6) 4 (1.5–6)
Months between PIB exams, median (range) 12 (11–13) 14 (14–17) 12 (9–14) 14 (12–23) 12 (9–12) 12 (9–25)
Months between MRI exams, median (range) 12 (11–13) 15 (13–17) 13 (11–15) 15 (14–23) 12 (11–12) 12 (12–28)
Diagnosis at second PIB exam, no. (%)
a
Cognitively normal 10 (100) 9 (90) 1 (5) 1 (11) 0 0
MCI 0 1 (10) 14 (70) 5 (56) 0 0
Alzheimer’s disease 0 0 5 (25) 3 (33) 4 (100) 4 (100)
a Missing data: three Mayo amnestic MCI and three Mayo AD subjects missing APOE e4 status; one ADNI CN missing CDR-SB; one ADNI CN and three ADNI amnestic
MCI subjects missing diagnosis at second PIB exam.
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mance distributions did not differ at the P50.05 level by source
of subjects. Overall—i.e. Mayo and ADNI subjects combined—
cognitively normal and amnestic MCI subjects were slightly older
than Alzheimer’s disease; and APOE 4 carriers were less common
in cognitively normal than in amnestic MCI subjects. Twenty-eight
percent of amnestic MCI subjects progressed to a diagnosis of
Alzheimer’s disease and two amnestic MCI subjects reverted to
a diagnosis of cognitively normal at the time of the second
imaging study. On average cognitively normal subjects performed
best on the MMSE and CDR-SB, Alzheimer’s disease worst and
amnestic MCI intermediate (each P50.01). Intervals between
baseline and follow-up PIB and MRI studies did not differ by
clinical diagnosis group; with one exception, the MRI interval
was slightly greater in amnestic MCI than Alzheimer’s disease.
Both PIB and MRI inter-scan intervals differed by source of
subjects (P50.001) and were on average 3 months greater for
Mayo compared to ADNI cognitively normal and amnestic MCI
subjects.
Baseline PIB and MRI ﬁndings by
clinical group and source of subjects
Baseline PIB data are illustrated in Fig. 1 and Table 2, with
accompanying P values for group differences in Table 3 and for
source differences in Supplementary Table E2. There were no
within group differences in baseline global PIB retention between
Mayo and ADNI sources (Supplementary Table E2). Among all
subjects, median PIB retention values at baseline differed signiﬁ-
cantly by clinical group (overall test, P=0.01) and were ordered,
Alzheimer’s disease4amnestic MCI4cognitively normal (Fig. 1).
Taking a global PIB cortical to cerebellar ratio value of 1.5 as a
cutoff denoting PIB ‘positivity’, 6/21 (29%) cognitively normal
subjects were PIB positive. Out of 32, 19 (59%) amnestic MCI
subjects were PIB positive. A single ADNI subject labelled clinically
as Alzheimer’s disease was PIB negative (presumably a clinical
misdiagnosis). Baseline PIB retention ratio values were greater
among amnestic MCI APOE 4 carriers than non-carriers
(P=0.003), but did not differ between carriers and non-carriers
among cognitively normal and Alzheimer’s disease subjects.
Baseline MRI data are illustrated in Fig. 1 and Table 2, with
accompanying P-values for group differences in Table 3, and for
source differences in Supplementary Table E2. Baseline ventricular
volume is expressed as a percentage of total intra-cranial
Figure 1 Baseline global cortical PIB ratio and baseline
ventricular volume by clinical diagnosis. Global PIB represents
a weighted average of the pre-frontal, temporal, parietal,
cingulate precuneus, anterior cingulate and orbito frontal
regions normalized to cerebellar retention. Baseline ventricular
volume is expressed as a percentage of TIV in each subject.
Boxes represent the 25th, 50th and 75th percentiles of the
data. Individual points have been randomly shifted along the
horizontal axis to reduce overlap.
Table 2 Median (ﬁrst quartile, third quartile) global cortical PIB and ventricular volume values by clinical group
Variable Cognitively normal Amnestic mild cognitive impairment Alzheimer’s disease
Global cortical to cerebellar PIB ratio
Baseline 1.3 (1.2, 1.6) 1.8 (1.3, 2.1) 2.0 (1.9, 2.1)
Annual change 0.05 (0.0, 0.10) 0.03 (0.03, 0.12) 0.06 (0.0, 0.10)
Ventricular volume
Baseline volume,% of TIV 2.9 (2.4, 3.5) 3.2 (2.6, 4.4) 3.6 (3.4, 4.0)
Annual change, cm
3 1.3 (0.4, 1.8) 2.5 (1.3, 4.6) 7.7 (4.0, 12.0)
Mayo and ADNI data have been combined.
Table 3 P-values for group-wise differences in global
cortical PIB and ventricular volume
Pairwise by diagnosis
a
Variable Differences
among
three
groups
b
CN
versus
aMCI
CN
versus
AD
aMCI
versus
AD
Global cortical to cerebellar PIB ratio
Baseline 0.01 0.02 0.003 0.40
Annual change 0.90 0.79 0.90 0.65
Ventricular volume
Baseline volume,% of TIV 0.19 0.39 0.04 0.31
Annual change, cm
3 50.001 0.01 50.001 0.004
Mayo and ADNI data have been combined.
CN=cognitively normal; aMCI=amnestic mild cognitive impairment;
AD=Alzheimer’s disease.
a Two-group Wilcoxon rank sum test.
b Three-group Kruskal–Wallis test.
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in head size. On average, ventricle/total intra-cranial volume
values were ordered, cognitively normal 4 amnestic MCI 4
Alzheimer’s disease; however, only Alzheimer’s disease versus
cognitively normal reached group-wise signiﬁcance (P=0.04).
Baseline ventricle/total intra-cranial volume values did not differ
by source of subjects.
Rates of change in PIB retention by
clinical group, source of subjects and
baseline PIB retention level
Annual rate of change in global PIB retention ratio is reported in
Table 2 and Fig. 2, with accompanying P values for group differ-
ences in Table 3 and for source differences in Supplementary
Table E2. The annual change in global PIB retention ratio did
not differ by source of subjects, P=0.81 (Supplementary
Table E2 and illustrated in Supplementary Fig. E2). Annual rate
of change in global PIB retention ratio over all groups was small
(average 0.042 units/year) and did not differ by clinical group
(overall, P=0.90) (Fig. 2, Tables 2 and 3). Annual rate of
change in global PIB retention ratio was signiﬁcantly greater
than zero over all subjects (P50.001), and individually among
cognitively normal (P=0.002), and amnestic MCI subjects
(P=0.008), with a trend in Alzheimer’s disease (P=0.11).
Annual rate of change in global PIB retention ratio was greater
among amnestic MCI subjects who were PIB positive at baseline
than those who were PIB negative (P=0.003); however, there
was no relationship between annual rate of change in PIB
retention and baseline PIB status (positive versus negative)
among cognitively normal subjects.
Across all subjects the correlation between the ﬁrst and second
PIB measurements was very high, with an intra-class correlation
of 0.98. The intra-class correlation for ventricular volume was
estimated at 0.99 suggesting that serial measures with both
modalities are reliable.
Throughout this manuscript PIB retention is reported as a global
cortical to cerebellar ratio which is quantiﬁed as the sum of uptake
in lobar cortical regions of interest divided by a cerebellar region of
interest. However, a question of interest is whether the annual
change in PIB retention differs by region. To address this question,
we plotted annual rate of change in PIB retention by region of
interest (Supplementary Fig. E2) for 10 different cortical regions of
interest with Mayo and ADNI subjects combined. There was no
obvious evidence that annual rates of change in PIB retention
differ by region of interest.
Rates of ventricular expansion by
clinical group, source of subjects
and baseline PIB retention level
Annual rate of ventricular change data are reported in Table 2 and
Fig. 2, with accompanying P values for group differences in
Table 3 and for source differences in Supplementary Table E2.
Annual rate of ventricular change did not differ by source of
subjects, overall test P=0.24 (Supplementary Table E2 and
illustrated in Supplementary Fig. E3). Rates of ventricular enlarge-
ment differed by clinical group (overall test, P50.001)
and increased in the following order, cognitively normal
(1.3cm
3/year) 5amnestic MCI (2.5cm
3/year) 5Alzheimer’s
disease (7.7cm
3/year). Pair-wise ventricular rate comparisons
were as follows: amnestic MCI4cognitively normal (P=0.01);
Alzheimer’s disease4cognitively normal (P50.001); and
Alzheimer’s disease4amnestic MCI (P=0.004). Ventricular expan-
sion rate was greater among amnestic MCI subjects who were PIB
positive at baseline than those who were PIB negative (P=0.02);
however, there was no relationship between annual ventricular
rate and baseline PIB status (positive versus negative) among
cognitively normal subjects.
PIB and ventricular annual rate of change are illustrated side by
side in Fig. 2 illustrating no group-wise differences in PIB rate
of change but clear group-wise scaling in ventricular expansion
rates. Supplementary Fig. E4 illustrates individual trajectories
of PIB retention ratio and ventricular volume over time in all
subjects by group. Over all subjects, the correlation between
PIB rate of change and ventricular rate of change was r=0.22
(P=0.10).
Correlations between rates of change
on imaging and change on continuous
measures of cognitive performance
When all subjects were combined there was no correlation
between PIB change and concurrent change on CDR-SB
(r=0.01, P=0.97) but perhaps some evidence of a correlation
between PIB change and MMSE (r=0.22, P=0.09). In contrast,
greater rates of ventricular expansion were clearly correlated with
Figure 2 Annual change in global PIB ratio and ventricular
volume by clinical diagnosis. Mayo and ADNI subjects have
been combined. Boxes represent the 25th, 50th and 75th
percentiles of the data. Individual points have been randomly
shifted along the horizontal axis to reduce overlap. PIB positive
subjects (baseline global cortical PIB 51.5) are represented
with triangles and PIB negative subjects (baseline global cortical
PIB 51.5) are represented with circles.
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MMSE (r=0.52, P50.01).
Discussion
The major ﬁndings from this study are as follows: (i) the PIB rate
of change was small but signiﬁcantly greater than zero in all
subject groups; (ii) the PIB rate of change did not differ by clinical
group. In contrast, ventricular rate did differ signiﬁcantly by
group and the group rates were ordered from greatest to least:
Alzheimer’s disease 4 mild cognitive impairment 4 cognitively
normal; (iii) both PIB and ventricular rates of change were greater
among amnestic MCI subjects who were PIB positive at baseline
than amnestic MCI subjects who were PIB negative at baseline
and (iv) ventricular rates of change correlated in the expected
direction with concurrent change on continuous measures of
cognitive and functional performance while evidence of a similar
correlation with PIB rates of change was unclear.
Study characteristics
Combining Mayo and ADNI data may raise questions about the
compatibility of data from these different sources. However, major
demographic variables—age, education, gender, APOE e4 and
cognitive and functional performance distributions—did not differ
signiﬁcantly between ADNI and Mayo subjects. From the imaging
perspective there were differences between subjects studied at
Mayo versus ADNI, the most obvious being the single versus
multi site nature of the two studies. Although the MRI sequence,
MPRAGE, was the same for ADNI and Mayo subjects, Mayo
subjects were scanned at 3T whereas ADNI subjects were scanned
at 1.5T. The acquisition window for PIB imaging was slightly dif-
ferent for Mayo versus ADNI subjects (40–60 versus 50–70min
post injection). However, the PIB cortical to cerebellar retention
ratio plateaus between roughly 45–90min (Lopresti et al., 2005).
Lopresti et al. (2005) found no appreciable effect of acquisition
window on the difference in PIB retention levels between
Alzheimer’s disease patients and controls over 40–90min.
Despite these technical imaging differences, the underlying
associations between imaging and biology did not vary substan-
tially by source of subjects. There were a number of similarities
between the ADNI and the Mayo studies that likely contribute to
the compatibility of data. For both ADNI and Mayo data, methods
of MRI pre-processing to correct image artifacts, the boundary
shift integral algorithm to calculate ventricular expansion, and
PIB quantitative analyses were all performed in an identical
manner using the same automated image processing pipelines at
Mayo. In addition, the operational deﬁnition of amnestic MCI was
the same for Mayo and ADNI subjects. This was not accidental as
methods used to categorize amnestic MCI that were developed at
Mayo were adopted by ADNI, and a Mayo investigator (RCP) is
the leader of the ADNI clinical core. Perhaps most importantly,
the compatibility of longitudinal imaging data from different
sources is greatly aided by the fact that all methods were held
constant within subject. Therefore, inter-subject differences in
methods tend to ‘wash out’ in longitudinal analyses of rates of
change.
Ventricular and baseline PIB ﬁndings
Group-wise PIB retention at baseline was ordered: Alzheimer’s dis-
ease4amnestic MCI4cognitively normal. Twenty-nine percent of
cognitively normal and 59% of amnestic MCI subjects were PIB
positive at baseline. Overall, these ﬁndings are in agreement with
previously published cross-sectional PIB studies (Nordberg, 2004;
Mintun et al., 2006; Kemppainen et al., 2007; Aizenstein et al.,
2008; Forsberg et al., 2008; Li et al., 2008; Mormino et al.,
2008; Sojkova et al., 2008; Villemagne et al., 2008).
Of greater interest are the relationships between baseline PIB
and longitudinal ventricular change. Ventricular rate of change
was greater in amnestic MCI subjects who were PIB positive
versus PIB negative at baseline. A reasonable explanation for this
combination of ﬁndings is simply that PIB positive amnestic MCI
subjects do have Alzheimer’s disease whereas PIB negative amnes-
tic MCI subjects do not (Archer et al., 2006; Forsberg et al.,
2008). This notion is reinforced by the fact that baseline PIB
ratio values were signiﬁcantly greater among amnestic MCI
APOE 4 carriers than non-carriers. PIB negative amnestic MCI
subjects by deﬁnition do have a (mild) cognitive impairment and
therefore must have one or more speciﬁc pathologies underlying
the impairment; however, the pathologies must be something
other than Alzheimer’s disease. Logical candidates include cerebro-
vascular disease, hippocampal sclerosis or Lewy body disease
(Bennett et al., 2005; Jicha et al., 2006; Schneider et al., 2007).
None of these non-Alzheimer’s disease pathologies are strongly
associated with rapid rates of brain atrophy, whereas Alzheimer’s
disease is (Whitwell et al., 2007). Therefore, the data on baseline
PIB and longitudinal ventricular change in amnestic MCI are con-
cordant overall in the following sense. Alzheimer’s disease-like
features clustered together—PIB positivity at baseline, high prev-
alence of APOE 4 carriers and rapid rates of brain atrophy.
Likewise, non-Alzheimer’s disease like features clustered
together—PIB negativity at baseline, low prevalence of APOE 4
carriers, and slower rates of brain atrophy.
We note that although baseline ventricular/total intra-cranial
volume ratio values were ordered in the expected manner,
cognitively normal 4 amnestic MCI 4 Alzheimer’s disease, only
Alzheimer’s disease versus cognitively normal reached pair-wise
signiﬁcance (P=0.04). In our experience, the ventricle boundary
shift integral is an excellent MRI measure of change over time
and, therefore, this was our choice of MRI metrics for longitudinal
assessment (Jack et al., 2004). However, cross-sectional ventricu-
lar measures are not particularly good indicators of disease severity
at a ﬁxed point in time (Jack et al., 2005). The focus of this article
is longitudinal measures of change. Baseline ventricular/total intra-
cranial volume values were included in the manuscript only to
create data presentation symmetry with baseline PIB values
which were of interest (speciﬁcally their relationship with longi-
tudinal PIB and MRI change). Had the article required a cross-
sectional MRI measure at baseline with the strongest association
with disease severity, we would have used the hippocampus, not
the ventricle (Jack et al., 1992).
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The major objective of this study was to evaluate concurrent MRI,
PIB and clinical change in the same subjects. Annual change in
MRI was expressed in units of volume (cm
3) and annual change in
PIB retention was expressed as cortical to cerebellar ratio units.
While these two metrics are unfortunately not directly compar-
able, these are the natural units of measurement for each of the
two modalities. Rates of ventricular expansion differed signiﬁcantly
by group and were ordered: Alzheimer’s disease4amnestic MCI4
cognitively normal, which implies acceleration in atrophy rate as
Alzheimer’s disease progresses clinically. We recognize that detect-
ing rate acceleration at the individual subject level requires three
or more separate measurements and we have two measurements
per subject in this study. However, earlier studies, in which three
or more unique measurements per subject were performed,
demonstrated acceleration in brain atrophy rates with clinical
progression of the disease (Chan et al., 2003; Ridha et al.,
2006; Carlson et al., 2008; Jack et al., 2008c). When cognition
was expressed as a continuous variable, concurrent measures of
cognitive change mapped well onto ventricular rate of change.
These longitudinal MRI ﬁndings are in agreement with an
accepted body of literature indicating good correlation between
rate of change in brain volume and concurrent clinical course (Fox
et al., 2000; Jack et al., 2000). In contrast, there was no apparent
correlation between PIB rate of change and CDR-SB, and minimal
evidence of a correlation between PIB rate of change and MMSE.
The two serial PIB studies published to date have both been in
Alzheimer’s disease subjects, and reported no appreciable change
in PIB retention over 2 years (Engler et al., 2006; Edison et al.,
2007). CSF AB 1–42 is inversely correlated with PIB retention
(Fagan et al., 2006), and therefore literature on CSF AB 1–42 is
relevant to a discussion of the relationships between brain amyloid
load and clinical disease expression. Inferences about the relation-
ship between CSF AB 1–42 and longitudinal disease progression
have been mixed (Clark et al., 2003; Wahlund and Blennow,
2003; Hampel et al., 2004; de Leon et al., 2006; Hansson
et al., 2006; Engelborghs et al., 2007; Fagan et al., 2007;
Sluimer et al., 2008). However, Andreasen et al. (1999) found
no relationship between CSF AB 1–42 and clinical disease duration
(a proxy for disease severity) in Alzheimer’s disease subjects.
Mirroring this ﬁnding, Ingelsson et al. (2004) found no relationship
between quantitative measures of cortical amyloid deposition at
autopsy and duration of clinical disease in Alzheimer’s disease
subjects. The net conclusion that can be drawn from this literature
is that an individual’s amyloid load accumulates prior to clinical
symptoms and reaches a plateau with no further accumulation
as the disease progresses clinically—i.e. amyloid load does not
increase in parallel with clinical disease progression. Our ﬁndings
agree with this model of disease to an extent, however, while we
found average rates of change in PIB were quite small, they were
positive and not zero.
We found that PIB rate of change did not differ signiﬁcantly by
clinical group, which suggests a linear rate of PIB accumulation
over time, at least late in life which was the age range of the
subjects we studied. It is possible that the rate of PIB (amyloid
deposition) is linear throughout life. At the rate we measured,
0.042 ratio units per year, it would take 23.8 years to move
from a negative PIB scan (cortical to cerebellar retention ratio
units=1.0) to the average level measured in Alzheimer’s disease
subjects (2.0 ratio units). Given our subjects’ ages, generally 60s
through 80s, this would mean that if amyloid accumulation
proceeded linearly, amyloid deposition in patients with typical
late-onset Alzheimer’s disease would have to begin in subjects in
their 40s. In contrast to this model, others (Ingelsson et al., 2004)
have proposed that the rate of amyloid deposition changes over
the course of the disease, speciﬁcally, that amyloid deposition rate
is rapid early and later ﬂattens to a plateau, after a threshold is
reached. Although our data do not seem to ﬁt this non-linear
model, we recognize that we do not have data that address
rates of PIB (amyloid) accumulation in middle age and earlier.
Figure 3 illustrates a model relating change on PIB, MRI and clin-
ical performance over time. The dotted lines in the early portion of
the amyloid curve indicate two possible trajectories which reﬂect
our uncertainty about this period in the disease course. However,
our data are consistent with a model in which amyloid deposition
proceeds at a slow linear rate late in life.
Imaging as an indicator of the time
dependent pathological changes in
Alzheimer’s disease
Our data are consistent with a model of typical late-onset
Alzheimer’s disease that has two main features, illustrated in
Fig. 3: (i) dissociation between the rate of amyloid deposition
and the rate of neurodegeneration late in life, with amyloid
Time
Pre-symptomic Prodomal
(MCI)
Dementia
Amyloid (PiB)
Cognition
Neuron / synapse numbers
(MRI)
Figure 3 Proposed model relating imaging, pathology
and clinical presentation over an individual’s adult lifetime.
The lifetime clinical course of the disease is divided into pre-
symptomatic, prodromal and dementia phases. Neurodegen-
eration, detected by MRI, is indicated by a dashed line.
Cognitive function is indicated by a dot-dash line. Amyloid
deposition, detected by PIB, is indicated by a solid line late in
life (i.e. that portion of the disease for which we have data).
The time course of amyloid deposition early in life is repre-
sented as two possible theoretical trajectories (dotted lines),
reﬂecting uncertainty about the time course of early PIB
deposition.
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eration accelerates; and (ii) clinical symptoms are coupled to
neurodegeneration not amyloid deposition. While signiﬁcant
plaque deposition occurs prior to clinical changes (Mintun et al.,
2006; Aizenstein et al., 2008), neurodegeneration (indicated by
atrophy on MRI) both precedes and parallels cognitive decline.
The presence of brain amyloidosis alone is not sufﬁcient to
produce cognitive impairment, as evidenced by data in the current
study as well as other independent studies that have consistently
found signiﬁcant PIB retention in up to 1/3 of cognitively normal
elderly subjects (Mintun et al., 2006; Aizenstein et al., 2008;
Gomperts et al., 2008; Jack et al., 2008b; Mormino et al.,
2008). The neurodegenerative element of Alzheimer’s disease
pathology is the direct substrate of cognitive impairment and the
rate of cognitive decline is driven by the rate of neurodegenera-
tion, a relationship also recently proposed by Mormino et al.
(2008). Evidence for this is our ﬁnding that ventricular rate of
change is correlated with concurrent change in cognitive and func-
tional performance, while PIB rate of change is not. This model of
disease implies a complimentary role for MRI and PIB imaging
clinically, with each reﬂecting one of the major pathologies
in Alzheimer’s disease, amyloid dysmetabolism and neuro-
degeneration. It also implies a complimentary role in clinical
trials. Longitudinal measures with MRI might be preferred as an
outcome measure to detect change in the underlying neuro-
degenerative pathology that tracks with clinical disease stage.
Conversely, PIB would be invaluable for selecting subjects for
amyloid modifying therapeutic trials.
Supplementary material
Supplementary material is available at Brain online.
Acknowledgements
The Alexander Family Alzheimer’s Disease Research Professorship
of the Mayo Foundation, USA.
Funding
National Institute on Aging (P50 AG16574, U01 AG06786, R01
AG11378 and AG024904); Robert H. and Clarice Smith and
Abigail Van Buren Alzheimer’s Disease Research Program of the
Mayo Foundation, USA.
References
Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND,
et al. Frequent amyloid deposition without signiﬁcant cognitive
impairment among the elderly. Arch Neurol 2008; 65: 1509–17.
American Psychiatric Association. Diagnostic and statistical manual of
mental disorders, DSM-IV. Washington, DC: American Psychiatric
Association; 1994.
Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B,
et al. Cerebrospinal ﬂuid beta-amyloid(1-42) in Alzheimer
disease: differences between early- and late-onset alzheimer disease
and stability during the course of disease. Arch Neurol 1999; 56:
673–80.
Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al.
Amyloid load and cerebral atrophy in Alzheimer’s disease: an 11C-PIB
positron emission tomography study. Ann Neurol 2006; 60: 145–7.
Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC,
Johnson KA, et al. Molecular imaging with Pittsburgh Compound B
conﬁrmed at autopsy: a case report. Arch Neurol 2007; 64: 431–4.
Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild
cognitive impairment is related to Alzheimer disease pathology and
cerebral infarctions. Neurology 2005; 64: 834–41.
Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA,
et al. The histological validation of post mortem magnetic resonance
imaging-determined hippocampal volume in Alzheimer’s disease.
Neuroscience 2000; 95: 721–5.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 1991; 82: 239–59.
Carlson NE, Moore MM, Dame A, Howieson D, Silbert LC, Quinn JF,
et al. Trajectories of brain loss in aging and the development of
cognitive impairment. Neurology 2008; 70: 828–33.
Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C, et al.
Change in rates of cerebral atrophy over time in early-onset
Alzheimer’s disease: longitudinal MRI study. Lancet 2003; 362:
1121–2.
Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al.
Cerebrospinal ﬂuid tau and beta-amyloid: how well do these biomar-
kers reﬂect autopsy-conﬁrmed dementia diagnoses? Arch Neurol
2003; 60: 1696–702.
Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado M, et al.
Correlations between antemortem hippocampal volume and postmor-
tem neuropathology in AD subjects. Alzheimer Dis Assoc Disord| 2004;
18: 190–5.
Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al.
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild
cognitive impairment. Neurobiol Aging 2006; 27: 394–401.
Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-
Schmid J, et al. Imaging of amyloid plaques and cerebral glucose
metabolism in semantic dementia and Alzheimer’s disease.
Neuroimage 2008; 39: 619–33.
Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al.
Amyloid, hypometabolism, and cognition in Alzheimer disease: an
[11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501–8.
Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De
Leenheir E, et al. No association of CSF biomarkers with
APOEepsilon4, plaque and tangle burden in deﬁnite Alzheimer’s
disease. Brain 2007; 130: 2320–6.
Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I,
et al. Two-year follow-up of amyloid deposition in patients with
Alzheimer’s disease. Brain 2006; 129: 2856–66.
Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al.
Inverse relation between in vivo amyloid imaging load and cerebro-
spinal ﬂuid Abeta42 in humans. Ann Neurol 2006; 59: 512–9.
Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.
Cerebrospinal ﬂuid tau/beta-amyloid(42) ratio as a prediction of
cognitive decline in nondemented older adults. Arch Neurol 2007;
64: 343–9.
Folstein MF, Folstein SE, McHugh PR. ‘‘Mini-mental state’’. A practical
method for grading the cognitive state of patients for the clinician.
J Psychiatr Res 1975; 12: 189–98.
Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al.
PET imaging of amyloid deposition in patients with mild cognitive
impairment. Neurobiol Aging 2008; 29: 1456–65.
Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial
registered brain magnetic resonance imaging to measure disease
progression in Alzheimer disease: power calculations and estimates
of sample size to detect treatment effects. Arch Neurol 2000; 57:
339–44.
Serial PIB and MRI in normal, MCI and AD Brain 2009: 132; 1355–1365 | 1363Freeborough PA, Fox NC. The boundary shift integral: an accurate and
robust measure of cerebral volume changes from registered repeat
MRI. IEEE Trans Med Imaging 1997; 16: 623–9.
Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE,
et al. Imaging amyloid deposition in Lewy body diseases. Neurology
2008; 71: 903–10.
Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA.
Hippocampal volume as an index of Alzheimer neuropathology:
ﬁndings from the Nun Study. Neurology 2002; 58: 1476–82.
Gunter JL, Shiung MM, Manduca A, Jack CR, Jr. Methodological con-
siderations for measuring rates of brain atrophy. J Magn Reson
Imaging 2003; 18: 16–24.
Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L,
et al. Core biological marker candidates of Alzheimer’s disease –
perspectives for diagnosis, prediction of outcome and reﬂection of
biological activity. J Neural Transm 2004; 111: 247–72.
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.
Association between CSF biomarkers and incipient Alzheimer’s disease
in patients with mild cognitive impairment: a follow-up study. Lancet
Neurol 2006; 5: 228–34.
Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC,
Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid
imaging in a typical case of Alzheimer’s disease. Brain 2008; 131:
1630–45.
Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET,
Frosch MP, et al. Early Abeta accumulation and progressive synaptic
loss, gliosis, and tangle formation in AD brain. Neurology 2004; 62:
925–31.
Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G,
Harvey D, et al. The Alzheimer’s Disease Neuroimaging
Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008a; 27:
685–91.
Jack CR, Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O’Brien PC, et al.
Antemortem MRI ﬁndings correlate with hippocampal neuropathology
in typical aging and dementia. Neurology 2002; 58: 750–7.
Jack CR, Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM,
et al. 11C PiB and structural MRI provide complementary information
in imaging of Alzheimer’s disease and amnestic mild cognitive
impairment. Brain 2008b; 131: 665–80.
Jack CR, Jr, Petersen RC, O’Brien PC, Tangalos EG. MR-based
hippocampal volumetry in the diagnosis of Alzheimer’s disease.
Neurology 1992; 42: 183–8.
Jack CR, Jr, Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, et al.
Rates of hippocampal atrophy correlate with change in clinical status in
aging and AD. Neurology 2000; 55: 484–89.
Jack CR, Jr, Shiung MM, Gunter JL, O’Brien PC, Weigand SD,
Knopman DS, et al. Comparison of different MRI brain atrophy rate
measures with clinical disease progression in AD. Neurology 2004; 62:
591–600.
Jack CR, Jr, Shiung MM, Weigand SD, O’Brien PC, Gunter JL, Boeve BF,
et al. Brain atrophy rates predict subsequent clinical conversion in
normal elderly and amnestic MCI. Neurology 2005; 65: 1227–31.
Jack CR, Jr, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC,
Cascino GD. Anterior temporal lobes and hippocampal formations:
normative volumetric measurements from MR images in young
adults. Radiology 1989; 172: 549–54.
Jack CR, Jr, Weigand SD, Shiung MM, Przybelski SA, O’Brien PC,
Gunter JL, et al. Atrophy rates accelerate in amnestic mild cognitive
impairment. Neurology 2008c; 70: 1740–52.
Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, Weiner MW,
et al. Neuropathological basis of magnetic resonance images in aging
and dementia. Ann Neurol 2008; 63: 72–80.
Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al.
Neuropathologic outcome of mild cognitive impairment following
progression to clinical dementia. Arch Neurol 2006; 63: 674–81.
Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK,
et al. Imaging of amyloid burden and distribution in cerebral amyloid
angiopathy. Ann Neurol 2007; 62: 229–34.
Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R,
et al. Reliability in multi-site structural MRI studies: effects of gradient
non-linearity correction on phantom and human data. Neuroimage
2006; 30: 436–43.
Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al.
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive
impairment. Neurology 2007; 68: 1603–6.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al.
Imaging brain amyloid in Alzheimer’s disease with Pittsburgh
Compound-B. Ann Neurol 2004; 55: 306–19.
Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test
of mental status. Correlations with standardized psychometric testing.
Arch Neurol 1991; 48: 725–8.
Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K,
et al. Assessment of beta-amyloid in a frontal cortical brain
biopsy specimen and by positron emission tomography with
carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65:
1304–9.
Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, et al.
Regional analysis of FDG and PIB-PET images in normal aging, mild
cognitive impairment, and Alzheimer’s disease. Eur J Nucl Med Mol
Imaging 2008; 35: 2169–81.
Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a
non-speciﬁc imaging marker of amyloid-beta (Abeta) peptide-related
cerebral amyloidosis. Brain 2007; 130: 2607–15.
Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al.
Simpliﬁed quantiﬁcation of Pittsburgh Compound B amyloid
imaging PET studies: a comparative analysis. J Nucl Med 2005; 46:
1959–72.
Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE.
Synthesis and evaluation of 11C-labeled 6-substituted
2-arylbenzothiazoles as amyloid imaging agents. J Med Chem
2003; 46: 2740–54.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM.
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-
ADRDA Work Group under the auspices of Department of Health
and Human Services Task Force on Alzheimer’s Disease. Neurology
1984; 34: 939–44.
Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al.
[11C]PIB in a nondemented population: potential antecedent marker
of Alzheimer disease. Neurology 2006; 67: 446–52.
Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL,
et al. Episodic memory loss is related to hippocampal-mediated
{beta}-amyloid deposition in elderly subjects. Brain 2008; Ahead of
print. ISSN 1460-2156; doi:10.1093/brain/awn320 (published online
28 November 2008).
Morris JC. The Clinical Dementia Rating (CDR): current version and
scoring rules. Neurology 1993; 43: 2412–4.
Nordberg A. PET imaging of amyloid in Alzheimer’s disease. Lancet
Neurol 2004; 3: 519–27.
O’Brien PC. The appropriateness of analysis of variance and multiple-
comparison procedures. Biometrics 1983; 39: 787–94.
Perneger TV. What’s wrong with Bonferroni adjustments. Bmj 1998;
316: 1236–8.
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al.
Current concepts in mild cognitive impairment. Arch Neurol 2001; 58:
1985–92.
Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al.
Beta-amyloid imaging and memory in non-demented individuals:
evidence for preclinical Alzheimer’s disease. Brain 2007; 130: 2837–44.
Rabinovici GD, Furst AJ, O’Neil JP, Racine CA, Mormino EC, Baker SL,
et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal
lobar degeneration. Neurology 2007; 68: 1205–12.
Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, et al.
Characterizing regional correlation, laterality and symmetry of
amyloid deposition in mild cognitive impairment and Alzheimer’s
disease with Pittsburgh Compound B. J Neurosci Methods 2008;
172: 277–82.
1364 | Brain 2009: 132; 1355–1365 C. R. Jack et al.Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al.
Tracking atrophy progression in familial Alzheimer’s disease: a serial
MRI study. Lancet Neurol 2006; 5: 828–34.
Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al.
Imaging beta-amyloid burden in aging and dementia. Neurology
2007; 68: 1718–25.
Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathol-
ogies account for most dementia cases in community-dwelling older
persons. Neurology 2007; 69: 2197–204.
Senjem ML, Lowe V, Kemp B, Weigand S, Knopman D, Boeve B, et al.
Automated ROI analysis of 11C Pittsburgh compound B images using
structural magnetic resonance imaging atlases. Alzheimer’s Dementia
2008; 4 (Suppl 1).
Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G,
et al. Changes in premorbid brain volume predict Alzheimer’s disease
pathology. Neurology 2003; 61: 487–92.
Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic
correction of intensity nonuniformity in MRI data. IEEE Trans Med
Imaging 1998; 17: 87–97.
Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van
der Flier WM, et al. Whole-brain atrophy rate and CSF biomarker
levels in MCI and AD: A longitudinal study. Neurobiol Aging 2008;
Ahead of print. ISSN 1558-1497.
Sojkova J, Beason-Held L, Zhou Y, An Y, Kraut MA, Ye W, et al.
Longitudinal cerebral blood ﬂow and amyloid deposition: an emerging
pattern? J Nucl Med 2008; 49: 1465–71.
Tang-Wai DF, Knopman DS, Geda YE, Edland SD, Smith GE, Ivnik RJ,
et al. Comparison of the short test of mental status and the
mini-mental state examination in mild cognitive impairment. Arch
Neurol 2003; 60: 1777–81.
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al.
Physical basis of cognitive alterations in Alzheimer’s disease: synapse
loss is the major correlate of cognitive impairment. Ann Neurol 1991;
30: 572–80.
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O,
Delcroix N, et al. Automated anatomical labeling of activations in SPM
using a macroscopic anatomical parcellation of the MNI MRI single-
subject brain. Neuroimage 2002; 15: 273–89.
Vemuri P, Whitwell JL, Kantarci K, Josephs KA, Parisi JE, Shiung MS,
et al. Antemortem MRI based STructural Abnormality iNDex
(STAND)-scores correlate with postmortem Braak neuroﬁbrillary
tangle stage. Neuroimage 2008; 42: 559–67.
Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, et al. Abeta
deposits in older non-demented individuals with cognitive decline are
indicative of preclinical Alzheimer’s disease. Neuropsychologia 2008;
46: 1688–97.
Wahlund LO, Blennow K. Cerebrospinal ﬂuid biomarkers for disease
stage and intensity in cognitively impaired patients. Neurosci Lett
2003; 339: 99–102.
Whitwell JL, Jack CR, Jr, Parisi JE, Knopman DS, Boeve BF, Petersen RC,
et al. Rates of cerebral atrophy differ in different degenerative
pathologies. Brain 2007; 130: 1148–58.
Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA,
Weigand SD, et al. MRI correlates of neuroﬁbrillary tangle pathology
at autopsy: a voxel-based morphometry study. Neurology 2008; 71:
743–9.
Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L,
et al. Correlates of hippocampal neuron number in Alzheimer’s
disease and ischemic vascular dementia. Ann Neurol 2005; 57:
896–903.
Serial PIB and MRI in normal, MCI and AD Brain 2009: 132; 1355–1365 | 1365